In summary, in this study, we demonstrated that some compounds from the ReFRAME and NPC libraries previously identified to have antiviral activity against different RNA virus families also inhibit VACV and MPXV, demonstrating their potential for the treatment of different viral infections. This evidence concerns the gene NPC1 and viral infectious disease.